JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designation May provide a

Read More